Generic placeholder image

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)

Editor-in-Chief

ISSN (Print): 1872-2148
ISSN (Online): 2212-3334

Affective Disorder and Hyperandrogenism

Author(s): Celen Zerouni, Elaine Kummerow, Mariflor Martinez, Ana Diaz, Uribe Ezequiel and Richard Wix-Ramos

Volume 7, Issue 1, 2013

Page: [77 - 79] Pages: 3

DOI: 10.2174/1872214811307010077

Price: $65

Abstract

A 40-year-old female patient with bipolar disorder and premenstrual dysphoric disorder did not present any physical evidence of virilization, treated with quetiapine and lithium carbonate. Laboratory testing showed evidence of hyperandrogenism (Testosterone levels 88.5ng/dL). After control, testosterone levels were normal (free testosterone 0.20 pg/ml, total testosterone 27.90ng/dl), as free thyroxine levels decreased (T4 0.83ng/dl) and increased progesterone levels (progesterone 3.80ng/ml). We consider an association between increased androgenic hormone levels in women, quetiapine and lithium carbonate treatment as well as the presence of an affective disorder and premenstrual dysphoric disorder. Some relevant patents are also outlined in this review.

Keywords: Affective disorder, hormonal alteration, hyperandrogenism, premenstrual dysphoric disorder, quetiapine and lithium carbonate treatment, Antiepileptic drugs, cognitive-affective disorders, hyperplasia, prostate cancer


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy